Search clinical trials for: HBM4003

Total 10 results

Harbour BioMed (Guangzhou) Co. Ltd.

Not yet recruiting

Study Investigating Safety,Tolerability,Pharmacokinetics and Antitumor Activities of HBM4003 Combine With Toripalimab

Solid Tumors
Harbour BioMed US, Inc.

Completed

A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of a Study Drug in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

Australia, China, Hong Kong
Harbour BioMed (Guangzhou) Co. Ltd.

Not yet recruiting

A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combine With Toripalimab in Patients With Advanced HCC and Other Solid Tumors

Solid Tumors
Harbour BioMed (Guangzhou) Co. Ltd.

Not yet recruiting

HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study

Solid Tumors
Harbour BioMed (Guangzhou) Co. Ltd.

Not yet recruiting

A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 Antibody

Solid Tumor
Cullinan Oncology Inc.
Harbour BioMed US, Inc.

Recruiting

CLN-418 Study on Subjects With Advanced Solid Tumors

Advanced Solid Tumor

Australia, United States
Xiangya Hospital of Central South University

Not yet recruiting

Safety and Efficacy Study of Parkinson's Disease Gene Therapy Drug (BBM-P002)

Parkinson's Disease

China
Sanofi
Procter and Gamble

Completed

Risedronate In The Prevention Of Osteoporosis In Osteopenic Postmenopausal Women

Osteoporosis, Postmenopausal

Netherlands, Sweden, Finland, Spain, Norway
Sanofi
Procter and Gamble

Completed

Risedronate in the Prevention of Osteoporosis in Postmenopausal Women

Osteoporosis, Postmenopausal

United States
Sanofi
Procter and Gamble

Completed

Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal Women

Osteoporosis Postmenopausal

France, United States, Australia, Canada, Lebanon, South Africa, Czech Republic, Turkey, Argentina, Poland, United Kingdom

3

Subscribe